Aura Biosciences, Inc. AURA
We are a clinical-stage biotechnology company developing precision therapies to treat solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with early choroidal melanoma (defined as small choroidal melanoma and/or indeterminate lesions) and is also in clinical development for other ocular oncology indications and bladder cancer.
There is significant unmet need for novel treatments for patients with choroidal melanoma, given the limitations of the current standard of care, or SoC, and patient reluctance to undergo radiotherapy in the form of either plaque brachytherapy or proton beam therapy, both highly-invasive therapies that result in significant vision loss, and potential legal blindness in the treated eye. Enucleation, or surgical removal of the affected eye, is another treatment option for patients with choroidal melanoma, in which patients lose all vision without the possibility of vision restoration. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in our ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early choroidal melanoma. Moreover, we intend to assess the safety and efficacy of bel-sar in treating a range of other solid tumors, beginning with metastases to the choroid and bladder cancer where bel-sar is in clinical development, as well as in cancers of the ocular surface. We believe bel-sar, if approved, has the potential to change the current treatment paradigm for patients with ocular and urologic cancers and other solid tumors.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $90.3M | $73.3M | $65.2M | $42.2M | $25.2M | $18.0M | — |
| SG&A | $22.5M | $22.8M | $19.8M | $18.1M | $10.1M | $4.2M | — |
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M | -$35.2M | -$22.2M | — |
| Pre-tax income | -$106.1M | -$86.8M | -$76.3M | -$58.8M | -$35.3M | -$22.2M | — |
| Income tax | $108.0K | $112.0K | $137.0K | $0 | $0 | $0 | — |
| Net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M | -$35.3M | -$22.2M | — |
| EPS, basic | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | — | — |
| EPS, diluted | -1.76 | -1.75 | -1.93 | -1.96 | -8.95 | -82.06 | — |
| Shares, diluted (wtd. avg.) | 60.3M | 49.7M | 39.6M | 29.9M | 5.2M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $59.5M | $31.7M | $41.1M | $121.6M | $149.1M | $17.4M | — |
| Total current assets | $149.7M | $160.6M | $231.8M | $196.7M | $153.7M | $18.5M | — |
| Property, plant and equipment | $2.6M | $3.2M | $3.1M | $5.4M | $5.3M | $3.6M | — |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M | $22.1M | — |
| Accounts payable | $1.5M | $2.3M | $1.8M | $2.9M | $2.4M | $611.0K | — |
| Total current liabilities | $18.4M | $14.9M | $12.4M | $10.5M | $7.4M | $2.7M | — |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M | $2.7M | — |
| Retained earnings | -$480.4M | -$374.2M | -$287.3M | -$210.9M | -$152.1M | -$116.9M | — |
| Total equity | $136.9M | $152.0M | $225.8M | $195.6M | $152.3M | -$108.7M | -$87.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$84.7M | -$79.8M | -$63.8M | -$54.6M | -$32.4M | -$24.3M | — |
| Depreciation and amortisation | $1.1M | $1.2M | $1.3M | $1.2M | $831.0K | $831.0K | — |
| Stock-based compensation | $14.3M | $11.7M | $8.8M | $6.4M | $2.3M | $736.0K | — |
| Capital expenditure | $447.0K | $1.3M | $709.0K | $1.1M | $2.1M | $771.0K | — |
| Investing cash flow | $35.6M | $68.8M | -$114.0M | -$67.9M | -$2.1M | -$771.0K | — |
| Financing cash flow | $77.2M | $1.6M | $97.3M | $95.6M | $166.3M | $10.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-130401.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$22.2M | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |